Codon-Optimized PUUV M Segment DNA Vaccine Plasmid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Puumala virus (PUUV) are ineffective in eliciting neutralizing antibodies and are unstable during plasmid amplification in E. coli, hindering the development of a reliable molecular vaccine.
Innovation Solution
A novel synthetic, codon-optimized Puumala virus full-length M segment open reading frame (ORF) is developed, altering five amino acid residues to enhance stability and immunogenicity, incorporated into a DNA vaccine plasmid (pWRG/PUU-M(s2)) that effectively elicits neutralizing antibodies in animal models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional killed-virus vaccines are used, then vaccine development is straightforward, but complete inactivation of infectivity without destroying protective epitopes is difficult to achieve
Solution Approach 1:
The patent extracts only the essential immunogenic components (Gn and Gc glycoproteins encoded by the M segment) from the complete virus particle. By using recombinant DNA technology to express only these protective epitopes in insect cells, the vaccine achieves complete safety (no infectivity) while preserving all necessary protective epitopes, thereby resolving the contradiction between complete inactivation and epitope integrity.
Solution Approach 2:
The patent creates a recombinant copy of the M segment gene and uses it to direct synthesis of Gn and Gc glycoproteins in insect cells. This molecular copy approach allows production of authentic viral epitopes without using the actual virus, ensuring both complete inactivation (no live virus) and epitope integrity (authentic glycoprotein structures).
2Reliability
If vaccinia-vectored vaccines are used, then protective immunity can be achieved, but the complexity of the vaccine system increases
Solution Approach 1:
The patent extracts only the M segment gene from the complete hantavirus genome and expresses it directly in insect cells using a simple baculovirus expression system. This eliminates the need for complex vaccinia virus vectors and multiple vaccination regimens, achieving protective immunity through a simplified two-dose vaccine regimen while reducing overall system complexity.
3Productivity
If protein subunit vaccines are expressed in bacteria, then production is efficient, but the complexity of purification and formulation increases
Solution Approach 1:
The patent uses insect cells as an intermediary expression system rather than bacteria. Insect cells naturally perform post-translational modifications (glycosylation, disulfide bond formation) that bacteria cannot perform, resulting in properly folded, native-like glycoproteins that self-assemble into immunogenic structures. This eliminates complex purification and formulation steps while maintaining high production efficiency.
Data Source
AI summary
The invention contemplates a new synthetic, codon-optimized Puumala virus (PUUV) full-length M gene open reading frame (ORF) that encodes a unique consensus amino acid sequence. The PUUV ORF was cloned into a plasmid to form the first stable PUUV full-length M gene that elicits neutralizing antibodies. The gene can be engineered into a molecular vaccine system, and is useful to protect mammals against infection with Puumala virus.